Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amylyx Pharmaceuticals Inc AMLX

Healthcare
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral... see more

Recent & Breaking News (NDAQ:AMLX)

INVESTOR ALERT: AMYLYX PHARMACEUTICALS, INC. (NASDAQ: AMLX) INVESTORS WITH LOSSES OF MORE THAN $100,000 ENCOURAGED TO SEEK APPOINTMENT AS LEAD PLAINTIFF - April 9, 2024 DEADLINE

PR Newswire March 25, 2024

Lost Money on Amylyx Pharmaceuticals, Inc.(AMLX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

Accesswire March 25, 2024

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 25, 2024

AMYLYX INVESTOR ALERT: Kirby McInerney LLP Alerts Amylyx Inc. (AMLX) Investors of Upcoming Lead Plaintiff Deadline in Class Action Lawsuit

Newsfile March 25, 2024

Levi & Korsinsky Reminds Amylyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 9, 2024 - AMLX

Accesswire March 25, 2024

Investors who lost money on Amylyx Pharmaceuticals, Inc. (AMLX) should contact Levi & Korsinsky about pending Class Action - AMLX

Accesswire March 25, 2024

UPCOMING AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!

Accesswire March 25, 2024

Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX) Seeking Recovery for Investors - Contact Levi & Korsinsky

Accesswire March 24, 2024

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire March 24, 2024

AMLX LAWSUIT ALERT: Levi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire March 24, 2024

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire March 24, 2024

UPCOMING AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!

Accesswire March 24, 2024

Levi & Korsinsky Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX

Accesswire March 23, 2024

ROSEN, A LONGSTANDING LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AMLX

Newsfile March 23, 2024

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Newsfile March 23, 2024

AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX

PR Newswire March 22, 2024

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile March 22, 2024

Amylyx Pharmaceuticals, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire March 22, 2024

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders

Accesswire March 22, 2024

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Newsfile March 22, 2024